Despite fervor, Lilly’s retatrutide not poised to supplant Mounjaro

Phase II data from Eli Lilly’s triple agonist retatrutide were lauded on social media as the most “astonishing results” yet for a weight loss treatment, but a closer look reveals retatrutide’s efficacy advantage may be marginal, while its worse tolerability profile could maintain Mounjaro’s status as the product to beat.

Eli Lilly and Co. (NYSE:LLY) presented late-breaking Phase II data on Monday for its latest obesity candidate, retatrutide, a peptide agonist of GLP-1R, GIP and GCG. The headline result was the mean weight loss of 24% at week 48 for the highest dose of 12 mg once-weekly. The Phase II data were presented at the American Diabetes Association (ADA) 83rd Scientific Sessions meeting and published in The New England Journal of Medicine...